Moffitt Cancer Center 20th Annual Clinical Breakthroughs and Challenges in Hematologic Malignancies 2025

• Target Audience: hematologists, oncologists
• Sample video: contact me for sample video
• Information:
• What You Will Learn

Attendees were able to:

Evaluate the latest clinical data regarding CAR T-cell therapy and bispecific antibodies, specifically their sequencing and toxicity management in lymphoma and myeloma.

Discuss the role of Measurable Residual Disease (MRD) testing in guiding treatment decisions for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).

Identify new therapeutic targets and agents for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma.

Analyze the “Hot Topics” in blood cancers, including the management of clonal hematopoiesis and its risk implications for older adults.

Debate controversial management strategies, such as the use of hypomethylating agents prior to transplant in high-risk MDS, through interactive pro/con sessions.

Implement best practices for managing complications of novel immunotherapies, including Cytokine Release Syndrome (CRS) and neurotoxicity (ICANS).

• Event Details

Date: January 25, 2025

Location: Florida (Historically held at venues like The Don CeSar in St. Pete Beach or Disney’s Grand Floridian in Orlando; the 21st Annual is confirmed for St. Pete Beach).

Organizer: Moffitt Cancer Center

• Who Should Attend

The conference is tailored for the interdisciplinary hematology-oncology team:

Hematologists and Medical Oncologists

Oncology Nurses and Nurse Practitioners

Physician Assistants

Pharmacists specializing in oncology/hematology

Research Scientists and Fellows

• Why Attend

Cutting-Edge Science: Moffitt Cancer Center is a leader in cellular therapy (CAR T), and this conference provides direct access to the faculty driving these innovations.

Debate Format: Unlike standard lecture series, this event features “Interactive Debates” (e.g., Transplant vs. CAR T in Myeloma), which help clinicians understand the nuance behind conflicting guidelines.

• Topics:

State-of-the-Art – Understanding Precursor States – CHIP and CCUS

2025 Updates on Treating Anemia in LR-MDS

Debate – Should MRD Status Be Used to Alter Treatment Decisions in High-Risk MDS & AML – Yes

Debate – Should MRD Status Be Used to Alter Treatment Decisions in High-Risk MDS & AML – No

Beyond CAR-T – Management of Post-BCMA CAR-T Relapse in RRMM

How I Treat High-Risk Multiple Myeloma – Interactive Case Discussion

AQUILA Trial – Daratumumab vs. Active Monitoring in SMM – Perspectives for Practice

Summary of Data for Transplant-Ineligible NDMM – Proposed SoC Approach

LR-MDS Updates + Panel Discussion – Focus on Ph3 IMerge Trial

Golcadomide + R-CHOP in High-Risk, Untreated Aggressive B-cell Lymphoma – Panel Discussion on Future of 1L Therapy in DLBCL